Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2179434
Max Phase: Preclinical
Molecular Formula: C43H83N15O8
Molecular Weight: 938.23
Molecule Type: Protein
Associated Items:
ID: ALA2179434
Max Phase: Preclinical
Molecular Formula: C43H83N15O8
Molecular Weight: 938.23
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C
Standard InChI: InChI=1S/C43H83N15O8/c1-23(2)20-31(52-27(9)59)38(63)56-33(22-25(5)6)40(65)57-32(21-24(3)4)39(64)54-30(16-13-19-51-43(48)49)37(62)58-34(26(7)8)41(66)55-29(14-10-11-17-44)36(61)53-28(35(45)60)15-12-18-50-42(46)47/h23-26,28-34H,10-22,44H2,1-9H3,(H2,45,60)(H,52,59)(H,53,61)(H,54,64)(H,55,66)(H,56,63)(H,57,65)(H,58,62)(H4,46,47,50)(H4,48,49,51)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
Standard InChI Key: NTGLPRTZQVMCKO-NXBWRCJVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 938.23 | Molecular Weight (Monoisotopic): 937.6549 | AlogP: -1.66 | #Rotatable Bonds: 33 |
Polar Surface Area: 396.61 | Molecular Species: BASE | HBA: 11 | HBD: 15 |
#RO5 Violations: 3 | HBA (Lipinski): 23 | HBD (Lipinski): 19 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.74 | CX Basic pKa: 11.63 | CX LogP: -2.67 | CX LogD: -9.52 |
Aromatic Rings: 0 | Heavy Atoms: 66 | QED Weighted: 0.02 | Np Likeness Score: 0.13 |
1. Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R.. (2012) The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells., 55 (23): [PMID:23126600] [10.1021/jm3011178] |
Source(1):